HC Wainwright Reiterates Buy Rating for Gossamer Bio

On Thursday, HC Wainwright reaffirmed their "buy" rating for Gossamer Bio (NASDAQ:GOSS) and set a price target of $10.00 for the stock, according to a research note. This comes as analysts continue to show confidence in the company’s potential for growth in the biopharmaceutical sector.

Recent Performance of Gossamer Bio Stock

On the same day, Gossamer Bio’s shares opened at $0.92. The stock has been trading below its moving averages, with the fifty-day moving average at $0.86 and the two-hundred day moving average at $0.90. Over the past year, Gossamer Bio has seen a low of $0.50 and a high of $1.60. Currently, the company has a market capitalization of approximately $208.15 million and a price-to-earnings (P/E) ratio of -2.87, indicating the company is not yet profitable. The stock's beta is 1.81, suggesting it is more volatile compared to the market. Additionally, Gossamer Bio has a debt-to-equity ratio of 3.64, as well as a quick ratio and a current ratio of 6.74, which reflect its liquidity position.

Quarterly Earnings Report

Gossamer Bio recently released its quarterly earnings report on November 7th. The company reported earnings of ($0.14) per share, which was better than analysts' expectations of ($0.18). Revenue for the quarter was reported at $9.48 million, significantly exceeding the expected $4.52 million. Analysts predict that the company will post an earnings loss of -$0.28 per share for this fiscal year.

Institutional Holdings and Investments

Several institutional investors have adjusted their positions in Gossamer Bio recently. In the third quarter, Jacobs Levy Equity Management Inc. boosted its holdings by 30.7%, now owning 1,887,512 shares. The Manufacturers Life Insurance Company also increased its stake by 24.2%, holding 385,133 shares. Other investors include GSA Capital Partners LLP and US Bancorp DE, which both purchased new shares in the period. Collectively, institutional investors hold 81.23% of the company's stock.

Overview of Gossamer Bio

Gossamer Bio, Inc. is a clinical-stage biopharmaceutical company that concentrates on developing seralutinib for treating pulmonary arterial hypertension (PAH) among other potential therapies. The company is also working on GB002, an inhaled small molecule designed to target platelet-derived growth factor receptors (PDGFR), colony-stimulating factor 1 receptor, and c-KIT, which is currently in Phase 3 clinical trials focused on PAH treatment.

Considerations for Investors

Investors looking to allocate funds should conduct thorough research before making decisions. While Gossamer Bio currently enjoys a buy rating, other analysts have identified several stocks that may pose more promising investment opportunities.

Gossamer, Stocks, Investment